<DOC>
	<DOCNO>NCT00045266</DOCNO>
	<brief_summary>RATIONALE : VEGF Trap may stop growth solid tumor non-Hodgkin 's lymphoma stopping blood flow cancer . PURPOSE : Phase I trial study effectiveness VEGF Trap treat patient relapsed refractory solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>VEGF Trap Treating Patients With Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine long-term safety tolerability VEGF Trap patient incurable relapsed refractory solid tumor non-Hodgkin 's lymphoma stable respond disease receive treatment protocol MSKCC-01131 . - Determine biological effect therapy suppress tumor growth progression patient . - Determine steady state concentration VEGF Trap time patient . - Determine whether patient develop antibody therapy extend exposure . OUTLINE : This extension study patient show evidence stable disease complete partial remission complete treatment protocol MSKCC-01131 . Patients continue receive VEGF Trap subcutaneously weekly additional 6 month absence unacceptable toxicity . Patients receive treatment dose level protocol MSKCC-01131 . Patients follow approximately 30 day . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm incurable relapsed refractory solid tumor nonHodgkin 's lymphoma treat MSKCC01131 Must complete participation protocol MSKCC01131 visit 16 show evidence stable disease complete partial remission tumor burden evidence symptomatic deterioration No adverse event toxicity result discontinuation participation protocol MSKCC01131 If patient experience doselimiting toxicity , patient must demonstrate ability tolerate dose low dose prior entry study No known suspect squamous cell carcinoma lung No prior concurrent new neurological symptom CNS ( brain leptomeningeal ) metastases protocol MSKCC01131 PATIENT CHARACTERISTICS : Age 25 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL No severe uncontrolled hematologic condition Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN Alkaline phosphatase great 2 time ULN PT , PTT , INR normal Renal Creatinine great ULN No 1+ great proteinuria No severe uncontrolled renal condition Cardiovascular No severe uncontrolled cardiovascular condition Pulmonary No severe uncontrolled pulmonary condition Other No prior hypersensitivity reaction recombinant protein ( e.g. , VEGF Trap ) No severe uncontrolled gastrointestinal , immunological , musculoskeletal condition No severe uncontrolled psychiatric condition adverse social circumstance would preclude study No condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) No concurrent immunotherapy Chemotherapy No concurrent standard chemotherapy Endocrine therapy No concurrent adrenal corticosteroid except low dos replacement therapy patient previously receive suppressive dos adrenal insufficiency No concurrent systemic hormonal contraceptive agent Radiotherapy No concurrent radiotherapy Surgery Not specify Other At least 30 day since prior investigational therapy VEGF Trap No concurrent standard investigational anticancer agents No concurrent herbal supplement ( `` nutraceuticals '' ) No concurrent anticoagulant antiplatelet drug ( e.g. , warfarin , heparin , aspirin , nonsteroidal antiinflammatory drug ) except selective cyclooxygenase2 ( COX2 ) inhibitor analgesia No concurrent COX2 inhibitor tumor treatment prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>